China Manufacturer Strategy for Tajikistan: Registration and Post-Market Compliance Plan

1. Key takeaways

Tajikistan applies to medical devices a fully national single-track registration system — it is neither a member nor an observer of the Eurasian Economic Union, and products cannot obtain local access through registration certificates obtained in other member states. GRZAN sets out for Chinese manufacturers a strategic axis: schedule the whole process in reverse from the five-year validity of registration certificates under Article 17(6), while implementing four dimensions in parallel: entity structure, vigilance system, import arrangements and localization. The four unavoidable arrangements are: defining the registration certificate holder as the core node of responsibility (Article 17(6)), building a pharmacovigilance system covering devices (Article 20), scheduling re-registration in reverse from the import timing rule (Article 21(1)(3)), and planning GMP certificates on both the manufacturer and importer sides (Article 13(4)).

2. Legal basis

3. Expert insights

Insight 1: non-membership status means Tajikistan can only offer a single national track, and it also determines the independence of registration assets. In Kazakhstan and Kyrgyzstan, companies may choose between a national track and a Union track; in Uzbekistan and Tajikistan, only national procedures exist. The direct consequence is that a registration certificate obtained in Tajikistan cannot be mutually recognized with other markets, and conversely certificates from other markets cannot be used here. In a multi-country Central Asia plan, companies must treat Tajikistan as an independent project rather than an extension of a Union project.

Insight 2: the five-year validity under Article 17(6) should serve as the baseline for scheduling the whole process in reverse. The five years run from issuance, and Article 21(1)(3) takes the moment before entry into Tajikistan as the withdrawal test. Combined, re-registration must be scheduled well ahead of the certificate expiry date to cover goods in transit and in stock. As for specific lead times such as starting re-registration three months before expiry, no statutory basis has been located in Law No. 1893 or published departmental rules; it is a practical estimate.

Insight 3: the authorized person mechanism of Article 17(2) is the only statutory entry point for foreign manufacturers. The applicant may be the manufacturer or its authorized person. Combined with Article 26(3)(3) on imports for registration purposes and Article 20(3) on the reporting obligation of registration certificate holders, the role of the authorized representative expands from filing agent to ongoing compliance entity, and the selection standard should move from the ability to file to the ability to perform duties continuously.

Insight 4: the GMP exemption of Article 13(4) requires certificates held on both the manufacturer and importer sides. The exemption covers manufacturers and importers holding a GMP conformity certificate, and companies must budget separately for the importer-side certificate.

Insight 5: Article 17(11) is the only statutory fee exemption clause in the law, and its coverage is limited. The registration fee is exempted only in two scenarios: medicines for the diagnosis and treatment of rare diseases, and medicines and medical products imported as humanitarian aid and used to implement state health programs. Routine commercial imports fall outside the exemption, and all other rates follow the payment documents issued by the competent authority.

Insight 6: Article 47(1) places the manufacturer in the first order of liability for harm compensation. Where harm results from defective manufacture or false instructions for use, compensation is paid by the manufacturer. For exporters, the localized accuracy of the instructions can directly affect compensation liability and should not be left to the translation stage alone.

4. Practical recommendations

1. Treat Tajikistan as an independent project. As Tajikistan is neither a Union member nor an observer, do not share registration dossiers or schedules with other Central Asia markets.
2. Schedule the whole process in reverse from the five-year validity period. Under Article 17(6) and Article 21(1)(3), the re-registration schedule must cover goods in transit and in stock.
3. Select the local authorized representative against the standard of continuous performance. Under Article 17(2), Article 20(3) and Article 26(3)(3), the duties of the representative cover filing, communication and post-market reporting.
4. Prepare budgets and schedules for GMP certificates on both the manufacturer and importer sides. Under Article 13(4), certificates on both sides are required to obtain the batch assessment exemption.
5. Make localization of the instructions for use an independent quality control node. Under Article 47(1)(2) and Article 1(21), false instructions constitute an independent ground for compensation.
6. Do not presuppose fee exemptions for routine imports. Under Article 17(11), the statutory exemptions cover only rare disease medicines and humanitarian aid.
7. Keep tracking the official text of the 2026 to 2030 pharmaceutical industry program. Under Article 4(5) and the government meeting of May 28, 2026, the pace of localization policy affects medium and long-term planning.

5. Verification checklist

• □ Confirmed that Tajikistan is neither a member nor an observer state of the Eurasian Economic Union and that only national procedures apply
• □ Confirmed that registration certificates under Article 17(6) are valid for five years and scheduled the whole process in reverse
• □ Confirmed that the applicant under Article 17(2) may be the manufacturer or its authorized person
• □ Selected the local authorized representative against the standard of continuous performance (Article 20(3) and Article 26(3)(3))
• □ Prepared budgets for GMP certificates on both the manufacturer and importer sides (Article 13(4))
• □ Made localization of the instructions for use an independent quality control node (Article 47(1)(2))
• □ Confirmed that Article 17(11) is the only statutory fee exemption clause and does not apply to routine imports
• □ Established a tracking mechanism for the official text of the 2026 to 2030 pharmaceutical industry program
• □ Labeled lead times such as re-registration three months before expiry as a practical estimate, not statutory requirements

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com